Circulating FGF19 and FGF21 surge in early infancy from infra-to supra-adult concentrations

International Journal of Obesity

Volumn 39, Issue 5, 2015, Pages 742-746

  Sanchez Infantes D ^a,b   Gallego Escuredo, J M ^a,b   Diaz M ^a,b   Aragones G ^c   Sebastiani, G ^a,b   Lopez Bermejo A ^d,e   De Zegher, F ^f   Domingo, P ^g   Villarroya, F ^a,b   Ibanez L ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; SOMATOMEDIN C; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR;

APPROPRIATE FOR GESTATIONAL AGE; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HUMAN; INFANCY; INFANT; INSULIN BLOOD LEVEL; LONGITUDINAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL FOR DATE INFANT; ADIPOSE TISSUE; ADULT; BLOOD; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ADULT; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFANT; INFANT, NEWBORN; INSULIN RESISTANCE; MALE; OBESITY; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84928925497     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.2     Document Type: Article

References (36)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
2. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-437.
3. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al. Endocrine regulation of the fasting response by PPAR alpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-425.
4. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009; 150: 4931-4940.
5. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225.
6. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624.
7. Novotny D, Vaverkova H, Karasek D, Lukes J, Slavik L, Malina P et al. Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome. Physiol Res 2014; 63: 219-228.
8. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203-206.
9. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58: 1532-1538.
10. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333-340.
11. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, Micanovic R et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012; 7: e38438.
12. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011; 152: 2996-3004.
13. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018-6027.
14. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD et al. Different roles of N-and C-termini in the functional activity of FGF21. J Cell Physiol 2009; 219: 227-234.
15. Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-? agonist treatment. Physiol Res 2011; 60: 627-636.
16. Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt M, Frühbeck G et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) 2015; 39: 121-129.
17. Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36: 1859-1864.
18. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 2013; 78: 489-496.
19. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542-1546.
20. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 2011; 27: 286-297.
21. Hanks LJ, Casazza K, Ashraf AP, Wallace S, Gutiérrez OM. Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females. Clin Endocrinol (Oxf) 2014; e-pub ahead of print 10 July 2014; doi:10.1111/cen.12552.
22. Ko BJ, Kim SM, Park KH, Park HS, Mantzoros CS. Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children. Int J Obes (Lond) 2014; 38: 1497-1502.
23. Bisgaard A, Sørensen K, Johannsen TH, Helge JW, Andersson AM, Juul A. Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents. Int J Pediatr Endocrinol 2014; 2014: 7.
24. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPAR alpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 2010; 11: 206-212.
25. Levin BE. Metabolic imprinting: critical impact of the perinatal environment on the regulation of energy homeostasis. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1107-1121.
26. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115: e290-e296.
27. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007; 165: 849-857.
28. Kerkhof GF, Hokken-Koelega AC. Rate of neonatal weight gain and effects on adult metabolic health. Nat Rev Endocrinol 2012; 8: 689-692.
29. Ibáñez L, Sebastiani G, Lopez-Bermejo A, Diáz M, Gómez-Roig MD, de Zegher F. Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin, and insulin growth factor-I at term birth: relation to prenatal growth. J Clin Endocrinol Metab 2008; 93: 2774-2778.
30. Ibáñez L, Sebastiani G, Diaz M, Gómez-Roig MD, Lopez-Bermejo A, de Zegher F. Low body adiposity and high leptinemia in breast-fed infants born small-forgestational-age. J Pediatr 2010; 156: 145-147.
31. Ferrández-Longás A, Mayayo E, Labarta JI, Bagué L, Puga B, Rueda C et al. Estudio longitudinal de crecimiento y desarrollo. Centro Andrea Prader. Zaragoza.
32. Garciá-Dihinx A, Romo A, Ferrández-Longás A (eds) Patrones de crecimiento y desarrollo en Espanã. Atlas de gráficas y tablas. 1st edn. Madrid: ERGON, 1980-2002; pp 61-115.
33. de Zegher F, Sebastiani G, Diaz M, Sánchez-Infantes D, Lopez-Bermejo A, Ibáñez L. Body composition and circulating High-Molecular-Weight adiponectin and IGF-I in infants born small for gestational age: breast-versus formula-feeding. Diabetes 2012; 61: 1969-1973.
34. Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez MM, Mateo MG, Fernandez I et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010; 24: 2629-2637.
35. Boehm G, Senger H, Müller D, Beyreiss K, Raïhä NC. Metabolic differences between AGA-and SGA-infants of very low birthweight. III. Influence of postnatal age. Acta Paediatr Scand 1989; 78: 677-681.
36. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17: 779-789.